PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.03.1154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2012English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open
Medicine
2015English

Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2016English

Effectiveness and Cost-Effectiveness of Erlotinib Versus Gefitinib in First-Line Treatment of Epidermal Growth Factor Receptor–activating Mutation-Positive Non–small-Cell Lung Cancer Patients in Hong Kong

Hong Kong Medical Journal
Medicine
2013English

Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2009English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy